Psychedelic Therapy Explained

Matthew: You know, I would say this goes for anything. So long as you're hanging in there and seeking treatment. It may not be this, it may be something else, but hang in there. Don't give up. That's the important thing. And don't see psychedelics as the only thing that's going to work.

Brent: Welcome to Death Clock. I'm your host, Brent Franson. Today we speak with Doctor Matthew Johnson about psychedelic therapy, exploring substances like psilocybin—commonly known as magic mushrooms—for mental health treatment. We cover the essentials of these psychedelics, their therapeutic applications, and dive into what you can anticipate from a psychedelic experience. This includes preparation before the journey, insights into dosing and the experience itself, and the crucial follow-up work post-journey.

Brent: This conversation is essential for anyone curious about the potential of psychedelic medicine in personal healing. Doctor Matthew Johnson is a professor of psychiatry and behavioral sciences at Johns Hopkins University and has recently embarked on a new venture as a senior investigator in psychedelics at Sheppard Pratt. He is one of the world's most published scientists on the human effects of psychedelics and has conducted seminal research in the behavioral economics of drug use, addiction, and risk behavior.

Brent: Doctor Johnson was the 2019 president of the Psychopharmacology and Substance Abuse Division of the American Psychological Association and is current president of the International Society for Research on Psychedelics. Doctor Johnson has been interviewed on Tim Ferriss, Huberman Lab, 60 Minutes, and in Michael Pollan's bestselling book, How to Change Your Mind. It's hard to find a better guest on this topic.

Brent: I hope you enjoy it as much as I did. Just a quick disclaimer: we are not recommending the use of any illegal substances, and even in a clinical setting, as you'll hear, there are a lot of different considerations that you need to be thinking about prior to embarking on this kind of journey. So we really want to get information about these medicines out into the world.

Brent: They hold a lot of potential, but there is a lot of legal and regulatory work yet to go before they're accessible to everybody.

Brent: Doctor Matthew Johnson, welcome to the show.

Matthew: Pleasure to be here. Thanks for having me.

Brent: Yeah. Today the topic is psychedelics, specifically the use of psychedelics for therapeutic purposes. I guess we'll probably touch on recreational use to some extent—it's part of the conversation, but that's not the main goal. I'd love to have a Psychedelics 101 here, and I can't think of anybody better to have on to discuss this.

Brent: So can you give us a quick sense of your potted bio, and then we'll dive in?

Matthew: Yeah. I'm an experimental psychologist—that's what my PhD is in—and I've been conducting research with drugs generally for over 25 years. For the last 20 years, I've conducted human psychedelic research, largely with psilocybin, the active agent in magic mushrooms, but also with some other psychedelic compounds. Most of that time, until pretty recently, has been primarily at Johns Hopkins.

Matthew: I've recently started a position at Sheppard Pratt Psychiatric Hospital, which has already been conducting some really great psychedelic work, to expand my psychedelic research. I've looked at the treatment of disorders such as depression, cancer-related anxiety and depression, and addiction in the form of tobacco addiction. So that's the short of it.

Brent: It's fascinating work. How do we define the term "psychedelics"? Mushrooms would come to mind very quickly. How would you define the term, specifically if we constrain that to psychedelics that we either know currently or believe will have some therapeutic benefit?

Matthew: The naming system is a point of incredible controversy, so you'll get different answers from different scientists. Psychedelics is a term that can be applied pretty broadly. It includes what someone like me would call the classic psychedelics. This is a group containing psilocybin (which is in mushrooms), LSD, mescaline (which is in various cacti, including peyote), and DMT (dimethyltryptamine, which is in the South American sacrament Ayahuasca).

Matthew: DMT is present in dozens and dozens of different plants. Those are the prototypical classic psychedelics, and we group them together because they have largely similar effects, mediated by the same basic mechanism: they activate a subtype of serotonin receptor in the brain, specifically the serotonin 2A receptor. But when we go outside those classic psychedelics, there are other compounds.

Matthew: Probably the biggest example is MDMA. It's not a classic psychedelic; it operates differently in the brain by releasing serotonin, so it's a serotonin releaser. Consistent with that different mechanism, it has somewhat overlapping but sufficiently different effects to put it in its own category. Then we have a whole variety of other compounds.

Matthew: Ibogaine is derived from an African bush, the iboga bush, and has a number of mechanisms of action in the brain. We have drugs like ketamine, which is an NMDA antagonist. Suffice it to say, it operates primarily on the glutamate system rather than the serotonin system.

Matthew: These systems are connected, so you can have downstream effects in common. Ketamine is actually approved for the treatment of depression; historically it was an anesthetic. There are countless other compounds we could go into, but those are the major examples of what we mean by psychedelic.

Brent: In terms of the psychedelics rising to the top for research and making their way into the mainstream conversation, it seems psilocybin and ketamine have a lead. Is that true? How do you think about the ones rising to the top that we're doing the most research on and are being most broadly used today?

Matthew: I'd add MDMA to that category, so those three would be the big ones. Again, it depends on how you count it, because plenty of scientists will argue that ketamine isn't a psychedelic and should be called something else. But if we count it as a psychedelic, it's ahead of the pack because it was approved several years ago—specifically Spravato, a nasal spray enantiomer of ketamine approved for depression. Ketamine itself has been approved for decades as an anesthetic, but Spravato was specifically FDA-approved for depression, so that's on the market.

Matthew: Out of the rest, MDMA has a significant lead over psilocybin. The FDA has accepted the Phase 3 package for MDMA for treating PTSD, meaning they're not going to require more data prior to decision. They have about six months to say yes or no on approval. Psilocybin has been investigated for depression.

Matthew: I've done some of that work for cancer-related distress and various addictions, including tobacco and alcohol addiction. The most data supports the treatment of depression. It's a bit behind MDMA for PTSD, but within two or three years, psilocybin may be approved for depression.

Matthew: If the current trajectory holds, we'd probably see psilocybin evaluated next for treating addictions like tobacco and alcohol. All of this depends on the evidence, much of which is yet to be collected, and the FDA's decision.

Matthew: And then I would I would think if the trajectory that we sort of see now holds, then we'd probably see psilocybin in treating addictions. You know, and these have to be evaluated separately. But tobacco addiction, alcohol addiction, we may be, you know, within a year or two after that, psilocybin being approved for those all of this to be clear, is depending on the evidence and the, much of which is yet to be collected.

Matthew: And the FDA's decision.

Brent: What's our sense, given research today, of the breadth of applicability for something like psilocybin? Going through FDA trials requires targeting specific conditions, like depression.

Brent: What is our hope or sense directionally regarding the breadth of applications? We've talked about depression, anxiety, and addiction. Where do you see this being helpful in the future?

Matthew: It all needs to be tested individually, but the transdiagnostic potential is remarkable—the promise of potentially treating a large number of disorders based on how it works. I would say anything associated with the need for behavior change, including thought patterns, which have both behavioral and cognitive correlates in these disorders.

Matthew: When framed that way, it covers most recognized psychiatric disorders. For any addiction, there's good reason to think this could be brought to bear, including methamphetamine or cocaine addiction.

Matthew: Also opioid addiction, tobacco, e-cigarettes or vaping, and cannabis addiction. Moving outside of that, whether the DSM considers them addictions or not is just evolving language, but I consider behavioral addictions as well.

Matthew: That includes sexual addictions—difficulty constraining behavior around pornography, sex workers, or reckless encounters—as well as gambling and obesity (which involves relationship to food, whether binge eating disorder or broader obesity).

Matthew: All of that needs to be tested, but there's strong potential. Outside of substance use or behavioral addictions, we have affective disorders. Most work has been done with depression.

Matthew: Recently, my colleague Scott Aaronson published a pilot study on bipolar disorder. More work is needed, but the initial fear that it might instigate a manic phase hasn't materialized so far. For other anxiety disorders, emerging work is underway, such as cancer-related distress studies and research into generalized anxiety disorder.

Matthew: I think there's good potential for anxiety disorders broadly speaking. It won't work for everything or everyone, and it has to be done right, but it's exciting that many mental health disorders could potentially be helped by this treatment.

Brent: What do we know about the actual treatment process? What is the pre-work? If I'm in one of these studies, what happens before I take psilocybin, what is the dosage, what does the session look like, and what happens afterward?

Brent: Can you give us a start-to-finish overview of the process?

Matthew: There is screening. Some of that is specific to research studies and might be dropped once approved by the FDA for standard clinical treatment, but much of it is for safety. It's not going to be a treatment for everyone.

Matthew: We have a strong suspicion that conditions like schizophrenia should be excluded pending further research. While some anecdotal reports claim help, we must be extremely cautious and let research clarify that.

Matthew: Severe heart disease is another exclusion—not minimal, controlled hypertension, but severe cardiovascular issues. These drugs raise blood pressure and heart rate. People who shouldn't be shoveling snow or taking flights of stairs shouldn't be receiving high-dose psilocybin or MDMA sessions.

Matthew: For qualified individuals, preparation spans anywhere from 2 to 8 hours with the therapists who will be present during administration. This involves preparing the person for the drug experience and how to handle feeling overwhelmed.

Matthew: A big part is establishing rapport and trust so you're not with a stranger, as well as establishing clear clinical boundaries, which is critical. For specific treatments, like my work with tobacco use disorder, structured psychotherapy is included.

Matthew: We incorporate cognitive behavioral therapy (CBT) for smoking cessation as part of preparation. Some studies use minimal formal psychotherapy and focus primarily on preparation and rapport-building, which itself is highly therapeutic.

Matthew: On the session day, the person arrives early. We aim for a relatively stress-free environment, though participants are typically nervous. We warn them that it can be scary; at high doses, someone might feel like they are dying.

Matthew: Never underestimate a challenging experience. Most psilocybin research uses high doses that are physically safe for screened individuals but psychologically intense. People sometimes assume these are microdoses, but they are not.

Matthew: These doses are larger than typical recreational doses taken at a concert or festival. At this dose, people usually need to retreat to their tent because social interaction isn't fruitful; it's an internal, high-intensity dose.

Matthew: In basic research studies with experienced psychedelic users who provide comparative feedback, participants are often astonished by the intensity.

Matthew: They'll remark that we weren't kidding when we advised not taking it lightly, calling it the largest dose they've experienced.

Brent: Can you quantify that? What does that mean relative to a five-gram "heroic dose"?

Matthew: We use pure psilocybin rather than dried mushrooms. Historically, we adjusted by body weight, though pooled research suggests a fixed dose works well. It has typically been in the 30 to 40 mg range of pure psilocybin.

Matthew: Sometimes people confuse milligrams of pure compound with grams of dried mushroom material. 30 mg of pure psilocybin is the isolated active chemical, completely different from dried mushroom weight.

Matthew: 30 mg of pure psilocybin is roughly equivalent to 5 grams of dried mushrooms—what Terence McKenna coined the "heroic dose." It's significantly larger than a typical recreational dose.

Matthew: A typical recreational dose might be an eighth of an ounce (3.5 grams) split between two or three people. Taking 30 mg of psilocybin is like taking over five grams by yourself at one time.

Matthew: It's a very high dose, not to be underestimated. You can feel overwhelmed or have a bad trip. The greatest danger is doing something unsafe to yourself or others. In a controlled environment, those challenging moments often become valuable learning experiences.

Matthew: Using unguided in public or around strangers carries real risks. But in a safe setting with proper psychological support, difficult experiences can be navigated and integrated.

Matthew: A psilocybin session lasts about 6 hours. MDMA lasts about 4 to 5 hours, though some studies use a supplemental booster dose to extend effects.

Matthew: Partway through to extend the effects, as mentioned before.

Brent: After the pre-work, I arrive on a stress-free morning to take a high dose. What does the room look like? Do I wear eye shades? Is someone in the room with me?

Brent: Is music playing? What am I walking into, ideally?

Matthew: All of that. You are there with one or two trained facilitators and never left alone. They are available if needed to offer supportive physical contact, like holding a hand, when words fall short.

Matthew: We maintain strict clinical boundaries—simple hand-holding or a hand on the shoulder, avoiding bodywork to prevent boundary issues. Music plays through room speakers and headphones.

Matthew: This ensures continuity if headphones are removed. While classical music is traditional, I researched alternative playlists with drones and singing bowls and found little statistical difference.

Matthew: The alternative playlist actually trended slightly better, suggesting musical variety works well. Researchers have historically been conservative to maintain scientific credibility.

Matthew: We don't want to take unnecessary risks, but exploring varied musical selections is valuable. Controlled studies also require standardized music across groups to avoid confounding variables.

Matthew: The physical space is designed to feel like a comfortable living room rather than a clinical hospital room. Soft lighting, artwork, flowers, and drapes help transform the environment.

Matthew: Creating an inviting atmosphere is essential. We minimize medical instrumentation during therapeutic sessions to foster a human, welcoming setting rather than a sterile laboratory feel.

Matthew: We move away from white coats and hospital beds toward a comfortable, warm environment.

Brent: In personal therapeutic sessions I've experienced, rituals like burning sage or setting up altars were included to create a sense of ceremonial intention. Do you bring ritual elements into clinical settings?

Brent: It created a meaningful ritualistic framework for the journey. Is that incorporated clinically, or avoided?

Matthew: That raises an important point. Some early studies incorporated elements like that, but explicitly religious or spiritual additions should be patient-driven. Clinicians shouldn't project their personal spiritual interests onto participants.

Matthew: We should remain broadly inclusive and accommodating to all beliefs or lack thereof. I've seen these treatments benefit devout atheists, conservative fundamentalists, and New Age adherents alike.

Matthew: It works across diverse political and philosophical backgrounds. My approach is "bring your own"—whether a Buddha, crucifix, crystal, or scientific book. Let the participant drive any symbolic framework.

Matthew: If facilitators place specific religious iconography in the room, it can alienate participants of other faiths or non-religious backgrounds.

Matthew: Imposing specific spiritual constructs risks placing the clinician in an inappropriate guru or priestly role, which can lead to ethical vulnerabilities.

Matthew: Psychedelic experiences often evoke deep feelings of connection to the universe, God, or existence. That internal process should unfold naturally without clinician imposition.

Matthew: Our role isn't to impose philosophical materialism or spiritual doctrines, but to let the patient guide their own interpretation.

Matthew: If someone discusses a spiritual concept, facilitators support them without teaching or imposing outside constructs.

Matthew: I can explain pharmacology and clinical evidence, but regarding metaphysical questions, clinicians must remain humble. A participant's personal insight is as valid as anyone's.

Matthew: A warm, welcoming environment allows participants to bring whatever personal symbols or beliefs are meaningful to them without outside influence.

Brent: How much of the session is spent lying down with eye shades versus talking with facilitators?

Matthew: For psilocybin, roughly 80% to 90% is spent lying down with eye shades on. The goal is internal focus. Participants briefly take them off when using the restroom, which provides a natural break.

Matthew: We encourage participants to focus inward during the peak rather than trying to analyze or verbalize the experience in real time, saving reflection for post-session integration.

Matthew: If someone wants to talk, facilitators listen supportively, then gently encourage them to return inward when appropriate.

Matthew: MDMA sessions are about 50/50. MDMA has a more social, communicative profile. In PTSD trials, much of that interaction involves processing trauma and personal history directly with therapists.

Brent: Is group therapy ever used where multiple participants take high doses together? What are the benefits or drawbacks of group administration?

Matthew: There is significant clinical promise in group work. The standard 1-on-1 or 2-on-1 model is resource-intensive and expensive.

Matthew: Group models are standard in many traditional indigenous contexts and informal settings. A group layout allows facilitators to assist participants as needed, followed by shared group integration.

Matthew: This combines professional facilitation with peer support and community connection.

Matthew: While some studies have used group preparation and integration with individual dosing, simultaneous group administration requires careful clinical design and experienced group therapy leaders.

Matthew: Managing group dynamics requires expertise to ensure balanced participation and safety. Tapping into established group psychotherapy principles will be essential as research expands.

Matthew: I believe group administration holds great promise and may become a dominant clinical model in the future.

Brent: How does the session wrap up? As effects subside, when can someone drive home, and what does the rest of the day look like?

Matthew: For safety, participants cannot drive home afterward, similar to post-procedure rules for medical sedation. A designated friend or family member must pick them up, or staff accompanies them home.

Brent: Will that person notice anything unusual in your behavior?

Matthew: By discharge, active drug effects have resolved. However, participants are often still processing a profound psychological experience.

Matthew: We advise support persons that the participant might want to talk extensively or remain quiet, and to let them guide the conversation.

Matthew: Participants feel psychologically vulnerable and should keep their evening clear of work or social obligations, prioritizing rest and quiet decompression.

Matthew: Sleep comes naturally for most after psilocybin once the drug has cleared, though mind activity can delay it. Compounds like LSD, which have longer durations, present more sleep challenges due to lingering mild stimulant effects.

Matthew: LSD can cause mild lingering wakefulness late into the night even after core psychedelic effects subside.

Matthew: Psilocybin and MDMA are shorter-acting when taken in the morning. Many participants report exceptionally restful sleep afterward, having processed significant emotional weight.

Matthew: They feel a sense of relief after addressing long-standing psychological burdens.

Brent: What happens in the following days and weeks? Is follow-up integration structured similarly to pre-work, meeting again with clinicians to process the experience?

Matthew: Yes, integration work is standard. Participants meet with their facilitators the next day. We often assign brief written reflection notes to serve as a starting point for discussion.

Matthew: In integration sessions, facilitators review those reflections, asking supportive, non-leading questions to help participants process insights and translate them into meaningful life changes.

Matthew: Facilitators maintain clinical vigilance for any adverse psychiatric reactions, though severe issues are rare in screened protocols.

Matthew: Integration varies by study goal. In smoking cessation, integration connects session insights directly to behavior change and cigarette cravings.

Matthew: We ask participants to reflect on how session insights relate to their smoking behavior, encouraging commitment to their quit attempt.

Matthew: In our tobacco studies, weekly follow-up meetings continue for several weeks. Discussion shifts gradually from the psilocybin experience toward ongoing behavioral support.

Matthew: We reinforce cognitive behavioral therapy tools to support long-term smoking abstinence.

Brent: But not multiple journeys.

Matthew: Number of sessions varies across protocols. Our pilot smoking study evaluated three sessions over eight weeks. A subsequent study evaluated a single psilocybin session.

Matthew: Our ongoing multi-site NIH-funded study uses two sessions, which appears to be the optimal number. The third session in our pilot study added minimal incremental benefit.

Matthew: It seemed like two was enough.

Brent: Just diminishing returns. It's not harmful.

Matthew: Two sessions help optimize therapeutic outcomes. Due to natural variability in session experiences, a second session provides another opportunity for meaningful therapeutic breakthroughs.

Matthew: Two sessions is standard across most depression trials. Future research will further refine optimal treatment frequency.

Matthew: In our cancer study, many participants maintained benefits a year later, though some suggested occasional booster sessions might be helpful as benefits gradually diminish over time.

Matthew: While single interventions can produce long-lasting benefit, broader clinical populations with complex comorbidities may require periodic maintenance sessions.

Matthew: For treatment-resistant depression, optimal protocols might eventually involve periodic sessions every few months, tailored to individual symptom patterns.

Matthew: If symptoms begin to return, scheduled follow-up sessions can restore therapeutic progress.

Brent: How do you describe the experience to someone who hasn't tried it? It feels ineffable and difficult to articulate within ordinary waking consciousness.

Brent: Intellectual concepts seem to register on a deep visceral level—for instance, realizing deeply that you have internal resources and don't need external substances for emotional coping. How do you prepare participants for what to expect?

Brent: And that really resonates with me. And I know everybody's experience are different. So how do you, when somebody prior to going through this is saying, what's it going to be like? How do you respond to that?

Matthew: We explain the wide range of potential experiences without inflating expectations. Overselling benefits can create disappointment if a treatment isn't effective for a particular individual.

Matthew: It's important that participants don't view psychedelics as a single last-resort option, which can be dangerous.

Matthew: It is one potential option among others. Continuing to seek appropriate care is key. Psychedelics should not be viewed as a panacea.

Matthew: We describe the variety of possible experiences, including challenging aspects that people might not anticipate, such as feeling like they are dying or losing sanity.

Matthew: You could feel like it's like you don't even know what you could feel like you've gone insane. And these are things. It's hard to know what that even feels like. Hopefully most of us don't know what it's like to go insane or to or to actually feel like you're you may die, that day, you know? So, you know, some people do know what those experiences are like.

Matthew: We explain that the experience often lies beyond words, and past participants frequently note that pre-session descriptions couldn't fully capture the reality.

Matthew: Communicating this ineffability is essential for informed consent, helping participants understand how unusual and intense the experience can be.

Matthew: Some individuals decide after thorough safety disclosures that psychedelic therapy isn't for them, which is a valid choice. We never persuade hesitant individuals to participate.

Matthew: It isn't suitable for everyone. If someone decides against it after hearing safety warnings, that is appropriate.

Matthew: Many who choose to proceed feel appropriate apprehension. I often say that if participants aren't at least slightly nervous beforehand, we haven't adequately explained the intensity.

Matthew: This intervention should be taken seriously. Preparing participants thoroughly, including acknowledging its indescribable elements, is vital.

Brent: How do we measure clinical results? Standard depression scales like the PHQ-9 evaluate severity before and after. Studies in cancer-related existential anxiety show substantial reductions after moderate doses.

Brent: How do you quantify success, such as smoking cessation rates across trials?

Matthew: Measurement depends on the disorder. Substance use disorders provide objective biological markers. Tobacco research allows precise biochemical verification compared to alcohol self-reports.

Matthew: Breathalyzers or blood tests reflect short-term alcohol presence, whereas tobacco testing provides clearer confirmation of continuous abstinence.

Matthew: Urine and exhaled carbon monoxide samples provide a reliable multi-day window to verify abstinence.

Brent: Because the standard would be not relying on self-report.

Matthew: Self-reports combined with biological verification form the gold standard in addiction research, requiring agreement across all measures.

Matthew: For psychiatric disorders, validated clinician-administered rating scales are used. For depression, independent, blinded clinicians—who did not facilitate the dosing session—assess symptoms using instruments like the Hamilton Depression Rating Scale.

Matthew: Blinded raters reduce diagnostic bias. MAPS PTSD trials utilize the CAPS-5, a gold-standard clinician-administered PTSD scale.

Matthew: They use like the Caps five, which is that equivalent for PTSD, a gold standard validated, clinician administered, scale.

Brent: What percentage of participants achieve smoking cessation or clinical depression improvement in these trials?

Matthew: In our pilot smoking cessation study, 80% of participants were biologically verified as abstinent at 6 months, and 60% remained abstinent at 2.5 years—unusually high success rates.

Brent: 8% at six months.

Matthew: Our randomized trial comparing a single psilocybin session to nicotine replacement patch yielded over double the success rate: over 50% verified abstinence at 6 months for psilocybin compared to roughly 25% for nicotine patch.

Matthew: Nicotine patch outcomes around 25% are considered strong in addiction research, making the psilocybin comparison notable. Clinical response (often defined as a 50% symptom reduction) and clinical remission are standard outcome benchmarks.

Matthew: Across various studies, 60% to 80% of participants achieve clinical remission, with even higher percentages showing significant improvement.

Matthew: The large effect sizes and sustained benefits observed at 6 to 12 months post-treatment are particularly striking.

Brent: What percentage of participants express regret about participating in the study?

Matthew: Explicit regret is rare—my estimate would be under 1% across our trials.

Matthew: Across hundreds of participants, very few regret participating. A slightly higher percentage (a few percent) state they wouldn't repeat the experience, but still do not regret having done it.

Matthew: You know, that would might be more the few percent.

Brent: So participants expressing strong negative reactions are extremely rare?

Matthew: It's a very small number, but analyzing those cases helps refine safety screening and preparation. For example, some participants unexpectedly confronted historical trauma during sessions focused on other goals.

Matthew: Unresolved personal trauma can become a central theme of a session even when participating for smoking cessation, requiring substantial psychological processing.

Matthew: A few participants found confronting uninvited trauma distressing. That experience taught us to inform participants better regarding potential emotional material.

Matthew: Because individual experiences cannot be fully predicted, thorough preparation is critical. Crucially, we have not observed long-term harm, even among those who wished they had not participated.

Matthew: Regretting an intense experience is distinct from sustaining long-term psychological harm, which we have not seen in our clinical trials.

Matthew: So I think that's an important distinction.

Brent: It's worth noting that there is virtually no risk of fatal physiological overdose in these clinical settings.

Matthew: For over 95% of individuals without severe cardiovascular disease, psilocybin has no known direct lethal toxicity level. Physical injury from impaired behavior in unsafe environments remains the primary risk outside clinical settings.

Matthew: Unlike drugs that suppress respiration or cause acute organ failure, psilocybin does not carry direct organ toxicity at standard doses for healthy individuals. Rare vulnerabilities exist, however.

Matthew: The single documented fatal psilocybin overdose in medical literature involved a heart transplant recipient. Elevating blood pressure in severe cardiovascular cases is hazardous.

Matthew: Unregulated settings carry risks for individuals with undetected cardiovascular conditions, which thorough medical screening flags in clinical protocols.

Matthew: Transient blood pressure spikes carry risks for vulnerable heart patients. MDMA requires additional medical precautions regarding cardiovascular safety.

Matthew: As an amphetamine derivative, MDMA exerts sympathomimetic effects. While safe in screened clinical trials, higher doses or unmonitored settings carry real toxicity risks.

Matthew: MDMA toxicity resembles standard pharmaceutical compounds where excessive intake causes dangerous adverse events, necessitating clinical oversight.

Matthew: Psilocybin and LSD possess an exceptional level of physiological safety regarding acute lethal toxicity compared to most pharmaceuticals.

Matthew: Behavioral impairment remains the primary hazard. While recreational MDMA use carries overdose risks, fatal incidents remain statistically uncommon relative to substances like opioids.

Matthew: Adulteration, dehydration, and hyperthermia account for most non-clinical MDMA emergencies, whereas clinical settings mitigate these risks entirely.

Brent: Where can curious individuals find accurate information or legal options? High-dose ketamine, psilocybin, and MDMA work has been transformative for many people seeking therapeutic healing.

Brent: Psychedelic therapy provided impactful progress where traditional recovery methods were incomplete. Where can individuals turn to learn more safely and legally?

Brent: Is ketamine the primary legal option currently available, while psilocybin and MDMA await full regulation?

Brent: What's next?

Matthew: Currently, ketamine is the primary legally approved option—either via FDA-approved Spravato or off-label ketamine-assisted psychotherapy involving higher doses and structured integration.

Matthew: MDMA may be close to FDA approval for PTSD, followed by psilocybin in coming years. While I do not advise illegal activity, harm reduction principles emphasize safety for those seeking care.

Matthew: Key harm reduction factors include verifying substance purity and dose, ensuring a trusted interpersonal environment, screening cardiovascular health, and maintaining physical environmental safety.

Matthew: Environmental risks, such as retreat locations near dangerous physical hazards, should be carefully avoided during altered states.

Matthew: A secure setting, known purity, clear dosing, and trusted facilitators significantly reduce risk.

Matthew: Vetting providers thoroughly is essential, as boundary violations remain a serious concern across therapeutic contexts internationally.

Matthew: Gathering detailed information regarding practitioner trustworthiness and safety standards is critical when evaluating options.

Brent: Thank you for your research and for advancing this field. Therapeutic psychedelic work stands among the most promising emerging fields for mental health treatment and quality of life improvement.

Brent: So thank you so much for everything that you do. And thank you for your time.

Matthew: You're welcome.

Brent: Death Clock is recorded in Boulder, Colorado, produced by Patrick Andino, music by Patrick Lee, and hosted by yours truly, Brent Franson, founder and CEO of Dive Bar.